CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 62 enrolled
Drug / intervention
Repyflec cognitive remediation trainingbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01279070
NCT01279070Phase 4Completed

Efficacy of Repyflec Cognitive Remediation Group Training in Cognition, Functional Outcomes and Psychiatric Symptoms of Outpatients With Schizophrenia.

Fundació Sant Joan de Déu·interventional·Posted Jan 19, 2011·Updated Aug 23, 2013

In Brief

A Phase 4 clinical trial evaluating Repyflec cognitive remediation training for Indication for Modification of Patient Cognitive Status. Completed, enrolled 62 participants across 1 site.

Detailed Summary

The purpose of this study was to develop an integrative intervention for schizophrenia taking into account previous efficacious therapies. Thus, our aim was to evaluate the efficacy of our cognitive remediation group training: Problem Solving and Cognitive Flexibility training (REPYFLEC), focused to improve neurocognition and functioning in schizophrenia patients. We hypothesized that training executive function and metacognition would allow us to achieve improvements in neurocognition, functioning and psychiatric symptoms of patients with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 19, 2011
Enrollment StartSep 1, 2006
Primary CompletionJan 1, 2009
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.5 years ago

Interventions

Repyflec cognitive remediation trainingbehavioral

Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.